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Downregulation of Mcl-1 has anti-inflammatory
pro-resolution effects and enhances bacterial
clearance from the lung
CD Lucas1, DA Dorward1, MA Tait1, S Fox1,2, JAMarwick1, KC Allen1, CT Robb1, N Hirani1, C Haslett1,
R Duffin1 and AG Rossi1
Phagocytes not only coordinate acute inflammation and host defense at mucosal sites, but also contribute to tissue
damage. Respiratory infection causes a globally significant disease burden and frequently progresses to acute
respiratory distress syndrome, a devastating inflammatory condition characterized by neutrophil recruitment and
accumulation of protein-rich edema fluid causing impaired lung function. We hypothesized that targeting the
intracellular protein myeloid cell leukemia 1 (Mcl-1) by a cyclin-dependent kinase inhibitor (AT7519) or a flavone
(wogonin) would accelerate neutrophil apoptosis and resolution of established inflammation, but without detriment to
bacterial clearance. Mcl-1 loss induced human neutrophil apoptosis, but did not induce macrophage apoptosis nor
impair phagocytosis of apoptotic neutrophils. Neutrophil-dominant inflammation was modelled in mice by either
endotoxin or bacteria (Escherichia coli). Downregulating inflammatory cell Mcl-1 had anti-inflammatory, pro-resolution
effects, shortening the resolution interval (Ri) from 19 to 7 h and improved organ dysfunction with enhanced alveolar–
capillary barrier integrity. Conversely, attenuating drug-induced Mcl-1 downregulation inhibited neutrophil apoptosis
and delayed resolution of endotoxin-mediated lung inflammation. Importantly,manipulating lung inflammatory cellMcl-
1 also accelerated resolution of bacterial infection (Ri; 50 to 16h) concurrent with enhanced bacterial clearance.
Therefore, manipulating inflammatory cell Mcl-1 accelerates inflammation resolution without detriment to host defense
against bacteria, and represents a target for treating infection-associated inflammation.
INTRODUCTION
Neutrophils are short-lived key innate immune defense cells that
under basal conditions undergo apoptosis within hours.1
However, following an inflammatory challenge, neutrophils
are rapidly recruited to infected or damaged tissue where their
lifespan is extended by host-derived factors (e.g., granulocyte-
macrophage colony-stimulating factor), pathogen-derived fac-
tors (e.g., lipopolysaccharide (LPS)), local factors (e.g., tissue
hypoxia), and the process of transmigration itself to allow an
appropriate neutrophil response to injury.2 Following successful
control of tissue injury and/or infection, neutrophil function
must be terminated in a timely manner to prevent neutrophil-
mediated host tissue damage.3,4 This is achieved by the highly
regulated events of neutrophil apoptosis and subsequent uptake
and removal of apoptoticneutrophils by surroundingphagocytes
including tissue macrophages,5,6 allowing the return to tissue
homeostasis. Failure of these processes has pathological con-
sequences with deficient clearance of apoptotic neutrophils
leading to deleterious secondary necrosis with consequent
enhanced tissue injury.7 In addition, unresolved neutrophilic
inflammation is a hallmark of many inflammatory conditions
including sepsis, acute lung injury, and its severe counterpart
acute respiratory distress syndrome.8 Furthermore, the delay in
neutrophil apoptosis correlates with increasedmortality in sepsis
and sepsis-induced lung injury in humans,8 suggesting that
manipulating neutrophil apoptosis and subsequent clearance
(efferocytosis) may provide novel therapeutic strategies to
enhance resolution of infection-associated lung inflammation.
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Neutrophil apoptosis can be controlled by either the extrinsic
pathway upon ligation of a death receptor by its ligand (e.g.,
tumor necrosis factor (TNF), Fas ligand, and TNF-related
apoptosis-inducing ligand (TRAIL)) or by the intrinsic path-
way in response to numerous stimuli including changes in the
local environment and cytokine and pharmacological manip-
ulation.9–11 The intrinsic pathway is controlled by members of
the B-cell lymphoma 2 (Bcl-2) family, with neutrophils
expressing proapoptotic members including Bad, Bax,
Bak, Bid, Bim, and Puma, as well as antiapoptotic
members including Bcl-extra large (Bcl-XL), and myeloid cell
leukemia 1 (Mcl-1).11,12 The prosurvival member Mcl-1 is
short lived with levels of Mcl-1 increased, along with inhibition
of neutrophil apoptosis, by factors present at inflammatory
sites including granulocyte-macrophage colony-stimulating
factor and hypoxia. Furthermore, Mcl-1 expression is
increased in neutrophils from patients with severe sepsis,13
suggesting that modulating Mcl-1 levels may be a viable
therapeutic target for the treatment of neutrophil-dominant
inflammation.
Neutrophil levels of Mcl-1 are amenable to pharmacological
manipulation in vitro, with agents such as the archetypal cyclin-
dependent kinase (CDK) inhibitor, R-roscovitine, downregu-
lating Mcl-1 in tandem with the induction of neutrophil
apoptosis in vitro.14 Our group has previously shown that
R-roscovitine can reduce inflammatory cell numbers in diverse
models of inflammation,14 but the consequences on organ
function and host defense against invading pathogens as well as
the molecular events involved in vivo have not been previously
investigated. AT7519 is a novel CDK inhibitor drug that is
currently in clinical trials for cancer and is a potent inhibitor of
CDK5 and CDK9,15 both expressed at high levels in human
neutrophils.16 Other pharmacological agents such as polyphe-
nolic plant-derived flavones are also capable of downregulating
neutrophil Mcl-1 levels in vitro, leading to neutrophil
apoptosis.11 Here we investigate dynamic manipulation of
Mcl-1 in inflammatory cells in vivo to determine the resolution
of established neutrophilic inflammation. Downregulation of
Mcl-1 in vitro and in vivo drives neutrophil apoptosis and
subsequent macrophage clearance and thereby accelerates
resolution of established lung inflammation in mice, whereas
stabilization of Mcl-1 delays the resolution of pulmonary
inflammation. Furthermore, targeting Mcl-1 accelerates reso-
lution of established Escherichia coli lung infection along with
reduced bacterial lung burden, suggesting that, unlike con-
ventional anti-inflammatory therapies, this novel therapeutic
approach has anti-inflammatory effects concurrent with
enhanced bacterial clearance.
RESULTS
AT7519 induces rapid concentration-, time-, and
caspase-dependent human neutrophil apoptosis via
downregulation of Mcl-1 and is able to override the survival
effect of bacterial products
The novel CDK inhibitor AT7519 induced human neutrophil
apoptosis in a concentration- and time-dependent manner
(Figure 1a–c). AT7519 wasB100 times more potent than the
archetypal CDK inhibitor, R-roscovitine (half-maximal effective
concentration of AT7519 61.1 nM at 6 h vs. 4.8 mM for
R-roscovitine; Figure 1a and Rossi et al.14). Bacterial-derived
products including LPS promote human neutrophil survival
in vitro, but this could be overcome by AT7519 (Figure 1b),
with increased numbers of apoptotic neutrophils seen in
AT7519-treated groups. Similarly, AT7519 was also able to
override the survival effects of the Gram-positive bacterial-
derived products lipoteichoic acid (LTA) and peptidoglycan
(PepG) by induction of apoptosis (Supplementary Figure S1
online). AT7519-induced neutrophil apoptosis was caspase
dependent as apoptosis was blocked by the broad-spectrum
caspase inhibitors z-VADandQ-VD (Figure 1d), andAT7519-
induced DNA fragmentation was blocked by co-incubation
with z-VAD (Figure 1e). Furthermore, AT7519 accelerated
caspase-3 cleavage by 6 h (Figure 1f). AlthoughMcl-1 has been
described as a downstream target of activated caspases.17
AT7519 downregulated Mcl-1 both before the appearance of
cleaved caspase-3 (Figure 1f) and in the presence of caspase
inhibitors (z-VAD or Q-VD; Figure 1g). These observations
confirmed that AT7519-driven Mcl-1 downregulation was
occurring independently of, and upstream to, caspase
activation at these early time points. AT7519 also caused
time- and caspase-dependent apoptosis of mouse bone
marrow-derived neutrophils, preceded by downregulation
of Mcl-1 (Supplementary Figure S2). Mcl-1 levels also
declined in control neutrophils undergoing constitutive apo-
ptosis (Figure 1f), consistent with published literature.11,17
To confirm that Mcl-1 downregulation was a driving factor
in inducing neutrophil apoptosis, and not merely a con-
sequence of apoptosis, we used a neutrophil precursor cell
line (HL-60; human promyelocytic leukemic cell line) to
examine the role of Mcl-1 in induction of apoptosis. Similar
to primary human neutrophils AT7519 induced rapid
time-, concentration-, and caspase-dependent apoptosis in
HL-60 cells by downregulation of Mcl-1 (Supplementary
Figure S3A,B). Small interfering RNA (siRNA) knockdown
of Mcl-1 led to accelerated HL-60 cell death by apoptosis,
with Mcl-1 knockdown preceding the induction of cell
death (Supplementary Figure S3C–F). Furthermore, Mcl-1
siRNA-mediated apoptosis, but not the Mcl-1 knockdown
itself, was blocked by caspase inhibition with Q-VD,
further confirming both cell death by apoptosis and
caspase-independent Mcl-1 downregulation (Supplementary
Figure S3G,H).
AT7519-treated human macrophages do not undergo
apoptosis despite downregulation of Mcl-1
Following neutrophil apoptosis it is essential that rapid
phagocytosis ensues to prevent neutrophil progression to
secondary necrosis and release of histotoxic contents into host
tissues. AT7519 at concentrations that induced apoptosis of
neutrophils (0.1–10 mM) did not induce apoptosis of human
monocyte-derived macrophages (MDMs) (Figure 2a). This
was despite a concentration-dependent downregulation of
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Mcl-1 by AT7519 in MDMs (Figure 2b). AT7519-treated
MDMs were still functionally intact as they were able to
phagocytose apoptotic neutrophils even after prolonged
incubation (6–8 h) with AT7519 (Figure 2c), despite Mcl-1
loss by these times. AT7519 treatment of neutrophils enhanced
their phagocytosis that was dependent on the induction of
apoptosis as it was blocked by Q-VD treatment of neutrophils
(Figure 2d–f). Phagocytosis of both control and AT7519-
treated neutrophils was inhibited by preincubating MDMs for
30min with cytochalasin D (10 mM), an inhibitor of actin
polymerization (Figure 2f).
AT7519 enhances resolution of established neutrophilic
lung inflammation
To assess the ability of AT7519 to enhance resolution of
established neutrophilic inflammation in vivo, we used three
mouse models of pulmonary inflammation. Intratracheal (i.t.)
administration of LPS caused lung inflammation with peak
neutrophil influx at B24 h, before spontaneous resolution
(Figure 3a,b). Administration of AT7519 24 h after LPS
dramatically reduced total inflammatory cells in
bronchoalveolar lavage (BAL; Figure 3a), mainly because of
a reduction in neutrophils (Figure 3b). By 12 h after AT7519
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Figure 1 AT7519 induces concentration-, time-, and caspase-dependent human neutrophil apoptosis via myeloid cell leukemia 1 (Mcl-1)
downregulation and overrides lipopolysaccharide (LPS)-induced survival. (a) Neutrophils cultured with AT7519 for 6 h before analysis of Annexin-V/
propidium iodide (AnnV/PI) binding (n¼ 3). (b) Neutrophils cultured for 2–20 h with AT7519 (1 mM), LPS (100 ngml 1), or combined AT7519
and LPS before assessment of viability (AnnV/PI binding; n¼ 6). (c) Representative flow cytometry plots (AnnV/PI) for (i) control and (ii) AT7519-treated
(1mM) neutrophils at 8 h of culture. (d) Neutrophil apoptosis (AnnV/PI) assessed at 6 h after culture with AT7519 (1 mM), z-VAD (100 mM), or Q-VD
(10 mM) alone or in combination (nZ4). (e) DNA laddering assessed after 6 h of culture; lane 1, DNA marker 180 bp; lane 2, control neutrophils; lane 3,
AT7519 (1 mM); lane 4, AT7519 (1 mM) and z-VAD (100 mM). (f) Neutrophils aged for 2–8 h in either control media or AT7519 (1 mM) before western
blotting for Mcl-1 (40 kDa), cleaved caspase-3 (17/19 kDa), and b-actin (42 kDa). (g) Neutrophils aged for 4 h with AT7519 (1mM)±z-VAD
(100 mM) or Q-VD (10 mM) before western blotting. **Po0.01, ***Po0.001 compared with control; þþþPo0.001 compared with LPS alone; ###Po0.001
compared with AT7519 alone.
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treatment, total neutrophil numbers were less than a quarter of
untreated controls. This gave a resolution interval (Ri; the time
taken for neutrophil numbers to decline to half-maximal18,19)
for AT7519 of B7 h, whereas the Ri for control mice was
B19 h. AT7519-induced resolution occurred in tandem with
enhanced apoptosis of neutrophils (observed at 36 h; 12 h after
AT7519), and enhanced macrophage clearance of apoptotic
cells (Figure 3c,d), with representative cytocentrifuge prepara-
tions of BAL cells shown (Figure 3m–p). A transient decrease
in BAL total monocytes/macrophages was observed at 36 h
(Figure 3e) that was unchanged by 48 h. By 48 h, increasing
numbers of neutrophils in the control group were undergoing
apoptosis (Figure 3c), consistent with spontaneous resolution of
neutrophilic inflammation. By 24 h after AT7519 administra-
tion, BAL fluid total protein andBAL immunoglobulinM (IgM),
measures of alveolar–capillary barrier integrity, were signifi-
cantly reduced compared with controls (Figure 3f,i). By 36 h
(12 h after AT7519), histological appearances were also
improved (Figure 3g,h). Analysis of inflammatory cytokines
revealed that whereas TNF-a levels were unchanged with
AT7519 treatment, chemokine (C-C motif) ligand 2 (CCL-2)/
monocyte chemotactic protein-1 (MCP-1) and interleukin-6
(IL-6) levels were higher inAT7519-treated animals (Figure 3j–l).
Proresolution effects of AT7519 were also investigated
following i.t. administration of the Gram-positive bacterial
components LTA and PepG that signal predominantly
via TLR2. Administration of AT7519 at 24 h after
LTA/PepG led to a rapid reduction in total BAL cells and
BAL neutrophils, with a concurrent increase in BAL apoptotic
neutrophils and clearance of apoptotic cells as evidenced by
macrophages containing apoptotic bodies (Supplementary
Figure S4A–F). This gave a resolution interval of B4.5 h
in AT7519-treated mice vs. B19 h in control mice. In this
model, TNF-a and IL-6 levels were unaltered with AT7519
treatment, whereas CCL-2 and IL-10 were increased following
AT7519 administration (Supplementary Figure S4G–J).
AT7519 also improved tissue histology, and AT7519-
induced neutrophil apoptosis in vivo was further confirmed
using flow cytometric analysis of Annexin-V (AnnV) binding
of neutrophils (Ly6Gþ ve/F4/80 ve cells; Supplementary
Figure S4K–N).
To investigate whether AT7519 could also enhance resolu-
tion in nonsterile lung inflammation, and the consequences of
augmented neutrophil apoptosis on bacterial clearance, 1 106
colony-forming units (CFUs) of live E. coli were administered
i.t. with AT7519 given at 24 h. AT7519 was also able to enhance
resolution of established E. coli-induced lung inflammation
(Figure 4a,b) with aRi for AT7519 ofB16 h, whereas the Ri for
control mice was B50 h. AT7519 administration also led to
reduced lung interstitial neutrophils (Figure 4d) but did not
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Figure 2 AT7519 does not induce death or impair phagocytosis by human monocyte-derived macrophages (MDMs) despite downregulation of
myeloid cell leukemia 1 (Mcl-1), whereas AT7519-treated neutrophils are phagocytosed more readily. (a) MDMs were incubated with AT7519
or gliotoxin (250 ngml 1; included as a positive control) for 8 h before apoptosis assessment (Annexin-V/propidium iodide (AnnV/PI)). (b) MDMs were
incubated with AT7519 for 4 h before western blotting for Mcl-1 (40 kDa) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 37 kDa).
(c) Incubation of MDMswith AT7519 for either 6 h or 8 h before co-incubation of apoptotic neutrophils (AT7519 treated) and assessment of phagocytosis
(n¼ 3). (d, e) Representative flow cytometry plots (forward scatter vs. FL1 and FL1 histogram) for (d) MDMs incubated with control aged neutrophils
and (e) MDMs incubated with AT7519-treated (1 mM) neutrophils. (f) Cumulative data with neutrophils incubated in control media, AT7519 (1 mM),
Q-VD (10 mM), or combinations before assessment of phagocytosis in both control and cytochalasin D (CytoD; 10 mM)-treated MDMs (n¼ 3).
**Po0.01, ***Po0.001 compared with control and ###Po0.001 compared with AT7519-treated neutrophils (f).
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affect the numbers of BAL monocytes/macrophages
(Figure 4c) or circulating neutrophils (Figure 4e). AT7519
improved histological appearances with a reduction in the
predominantly perivascular inflammation seen in control
animals at 48 h (Figure 4f). Importantly, lung bacterial
counts were lower following AT7519 treatment, despite
AT7519 having no direct effect on E. coli growth
(Figure 4g–i). No bacteria were recovered from liver or
blood at this time point in either group (data not shown). To
investigate whether enhanced neutrophil apoptosis was
observed in our E. coli model, an earlier time point was
studied (30 h; 6 h after AT7519 administration). Flow
cytometric analysis of AnnV binding of BAL and interstitial
neutrophils (CD45þ ve/Ly6Gþ ve cells) revealed increased
apoptosis in AT7519-treated animals (Figure 4j–k). At this
time point Mcl-1 levels were reduced in BAL cells from
AT7519-treated animals, whereas levels of cleaved caspase-3
were increased (Figure 4l). Lung bacterial counts at this earlier
time point were identical between control and AT7519-treated
animals (130±16 vs. 127±15CFUml 1, P40.05).
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Figure 3 AT7519 accelerates resolution of established lipopolysaccharide (LPS)-mediated lung inflammation. At 24 h after intratracheal (i.t.)
administration of LPS,mice receivedAT7519 (30mg kg1 intraperitoneal (i.p.)) or vehicle control with acquisition and analysis of bronchoalveolar lavage
(BAL) fluid at indicated time points. (a) Total BAL inflammatory cells, (b) neutrophils, (c) apoptotic neutrophils, (d) macrophages containing apoptotic
bodies, (e) total monocytes/macrophages, and (f) BAL protein concentration at each time point are shown. Representative tissue sections at
36 h in panel (g) LPS alone and (h) LPS- and AT7519-treated animals (original magnification 200). (i) BAL immunoglobulin M (IgM) at 48 h after LPS.
BAL fluid was analyzed for the inflammatory mediators (j) tumor necrosis factor (TNF-a), (k) chemokine (C-C motif) ligand 2 (CCL-2)/monocyte
chemotactic protein-1 (MCP-1), and (l) interleukin-6 (IL-6). Representative cytocentrifuge preparations of BAL cells are shown (m) at 24 h after LPS
(original magnification 200) showing neutrophil predominant inflammation (n) at 36 h following LPS, control group (original magnification  1,000),
demonstrating normal neutrophil morphology, (o, p) at 36 h after LPS, AT7519-treated group (original magnification 1,000), showing (o) neutrophils
with apoptotic morphology (black arrows) with condensed nuclei and cellular shrinkage and (p) a macrophage containing two apoptotic bodies
(white arrow). At each time point, n¼5–6 mice per group, *Po0.05, **Po0.01, and ***Po0.001 compared with control at the respective
time point.
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Downregulation of Mcl-1 in vivo enhances resolution of
established neutrophilic inflammation
To further investigate whether Mcl-1 downregulation in vivo
was involved in the proresolution effects of AT7519, we used a
pharmacological inhibitor of the proteasome (bortezomib)20 to
reduce Mcl-1 degradation. Co-treatment with bortezomib
caused a concentration-dependent inhibition of AT7519-
induced human neutrophil apoptosis in vitro secondary to
maintenance of Mcl-1 levels (Figure 5a–d). Maintenance of
Mcl-1 levels also prevented the appearance of cleaved caspase-9
and caspase-3 (Figure 5d). Bortezomib also delayed
spontaneous neutrophil apoptosis consistent with previous
observations.11 In vivo treatment with bortezomib inhibited the
proresolution effects of AT7519 as it prevented AT7519-
mediated reductions in total BAL cells and neutrophils, and
prevented increases in neutrophil apoptosis and macrophage
clearance (Figure 5e–h). Bortezomib also blocked AT7519-
induced improvements in lung histology (Figure 5i–l). BAL
inflammatory cell Mcl-1 levels were reduced in vivo by AT7519
treatment, an effect attenuated by concurrent proteasomal
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Figure 4 AT7519 accelerates resolution of established Escherichia Coli-induced lung inflammation and improves lung bacterial titers.
At 24 h after intratracheal (i.t.) administration of 1 106 colony-forming units (CFUs) of E. coli, mice were treated with AT7519 (10mg kg1) or vehicle
control. Mice were killed at 48 h and (a) total bronchoalveolar lavage (BAL) inflammatory cells, (b) neutrophils, and (c) monocytes/macrophages
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AT7519 in E. coli alone or E. coli plus AT7519) were lysed and myeloid cell leukemia 1 (Mcl-1; 40 kDa), cleaved caspase-3 (17/19 kDa), and b-actin
(42 kDa) levels determined by western blotting. At each time point, n¼ 8–9mice per group were used, *Po0.05, **Po0.01, ***Po0.001 compared with
control.
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inhibition (Figure 5m). Total inflammatory cells were
unchanged at this early time point (Figure 5n), confirming
changes in Mcl-1 levels preceded alterations in inflammatory
cells.
To further investigate whether Mcl-1 downregulation was a
general mechanism driving resolution of inflammation or
whether this was specific to AT7519, we investigated the ability
of the natural flavone wogonin, which also reduces Mcl-1 in
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neutrophils in vitro,11 to accelerate resolution of lung
inflammation. Wogonin, when administered to established
neutrophilic inflammation, also caused enhanced resolution of
inflammatory cells in BAL, with enhanced apoptosis of
neutrophils and subsequent clearance by macrophages and
an improvement in alveolar–capillary barrier integrity as
measured by BAL IgM (Figure 6a–g). As with AT7519,
these changes were preceded by a decrease in Mcl-1 in vivo
(Figure 6h).
DISCUSSION
Neutrophil apoptosis and subsequent clearance of apoptotic
cells are key to the successful resolution of neutrophilic
inflammation, with dysregulation of these processes observed
in multiple human inflammatory diseases. Therefore, targeted
manipulation of defective resolution pathways, by timely
apoptosis of neutrophils and subsequent efferocytosis by
macrophages, may provide novel therapeutic strategies to
treat established mucosal inflammation. Lung injury can occur
following direct pulmonary insult such as infection, or be
caused by systemic insults including sepsis and trauma.
Subsequent to the inciting insult, uncontrolled inflammation
occurs with recruitment and activation of leukocytes as well as
increased permeability of the alveolar–capillary membrane
central to disease pathogenesis.21 Recruited neutrophils con-
tribute directly to the development and progression of lung
injury with higher neutrophil BAL counts associated with
enhanced mortality in humans,22 and neutrophil depletion or
blocking recruitment being protective in animal models of
acute respiratory distress syndrome.23–25 Here we have shown
that pharmacological downregulation of the intracellular
prosurvival molecule Mcl-1 drives neutrophil apoptosis and
subsequent macrophage efferocytosis in vitro, and that Mcl-1
downregulation in vivo accelerates resolution of established
neutrophil-mediated lung inflammation in mice.
Neutrophils are short-lived cells but their lifespan is
markedly extended at sites of inflammation. Proteins from
the Bcl-2 family are key controllers of the intrinsic (mito-
chondrial) pathway of apoptosis with neutrophils expressing
both pro- and anti-apoptotic Bcl-2 family members. The key
role that Bcl-2 proteins play in both neutrophil apoptosis and
control of inflammation has been previously highlighted by
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transgenic overexpression of Bcl-2 inmice that leads to delayed
neutrophil apoptosis, increased brain edema, hemorrhage, and
poorer outcomes during amodel of meningitis.26 Furthermore,
loss of proapoptotic Puma leads to lethal sepsis in a model of
Streptococcus pneumoniae infection.27 Under pathophysiolo-
gical circumstances, neutrophils can also dynamically alter Bcl-
2 family member expression with cytokine-mediated decreases
in proapoptotic Bax described as a way of enhancing neutrophil
longevity during proinflammatory conditions.28 This finding is
surprising, given that proapoptotic proteins like Bax have
relatively long half-lives, and that delayed neutrophil apoptosis
usually requires the ongoing synthesis of new proteins.12,16 This
suggests that synthesis of new antiapoptotic proteins may be
equally important for the delayed neutrophil apoptosis seen
during inflammation. Increased Mcl-1 may fit this role
given that several factors that extend neutrophil lifespan
(e.g., granulocyte-macrophage colony-stimulating factor and
hypoxia) also increase Mcl-1 expression.29,30 In addition, as
Mcl-1 has a short half-life (B3 h31), levels can be rapidly and
dynamically regulated by both the host and pharmacological
interventions.
Here we have demonstrated that the CDK inhibitor AT7519
induces rapid, caspase-dependent human and mouse neutro-
phil apoptosis in vitro by downregulation of Mcl-1, and
overrides survival signals fromGram-negative (LPS) and gram-
Positive derived (LTA and PepG) bacterial products. Mcl-1
levels were reduced by AT7519 by 4 h, immediately before
AT7519-induced apoptosis and the appearance of activated
caspase-3. Although Mcl-1 can be downregulated by activated
caspases in neutrophils, possibly acting as a positive feedback
loop, AT7519 reducedMcl-1 even in the presence of the caspase
inhibitors z-VAD or Q-VD. This confirms Mcl-1 loss as an
early and caspase-independent event in neutrophil apoptosis.We
also observed that Mcl-1 loss induced by siRNA was by itself
sufficient to drive apoptosis in a neutrophil precursor cell line.
Subsequent to induction of neutrophil apoptosis, it is
essential that apoptotic neutrophils are phagocytosed to
prevent progression to secondary necrosis with release of
histotoxic contents and consequent enhanced tissue injury. In
addition, the ingestion of apoptotic neutrophils by surrounding
macrophages serves as a signal to modulate cytokine and
proresolving lipid production, with alterations in lipid
mediator production important in the resolution of both
sterile inflammation and bacterial infection.19,32,33 Although
treatment of MDMs with AT7519 led to reductions in Mcl-1,
similar to others34,35 we found that this in itself did not induce
MDM apoptosis. This is in contrast to previous reports where
delivery of Mcl-1 antisense oligonucleotides to human
macrophages has been shown to directly induce apoptosis,
concurrent with a reduction inMcl-1 levels.36 In addition, Mcl-
1 loss in macrophages has been associated with induction of
apoptosis, although this may be also because of the observed
synchronous upregulation of an Mcl-1 splice variant with
proapoptotic activity.37 We also observed that MDMs that had
reduced Mcl-1 were still functional and able to phagocytose
apoptotic neutrophils in vitro. However, loss ofMcl-1 enhances
macrophage apoptosis upon subsequent phagocytosis of
bacteria34,37 that may explain the transient reduction in
macrophage numbers seen in vivo following AT7519 treatment
and phagocytosis of apoptotic neutrophils.
Although the myeloid-specific Mcl-1 knockout mouse has
low levels of circulating neutrophils, demonstrating a role for
Mcl-1 in neutrophil survival in noninflammatory circum-
stances, it is unclear whether this is because of a defect in
neutrophil survival or because of a blockage in granulocyte
maturation.34,35 Furthermore, the role of Mcl-1 in controlling
the resolution of acute inflammation and infection in vivo has
not been previously investigated. This is an important point
as stimulated, inflammatory neutrophils are known to
have altered control of apoptosis induction. For example,
TRAIL-deficient mice show normal circulating neutrophil
numbers and normal constitutive neutrophil apoptosis but
demonstrate impaired apoptosis when exposed to an inflam-
matory environment.38 Similarly, the apoptosis-inducing effect
of steroids on the closely related eosinophil granulocyte is lost
in the presence of factors such as IL-5 that are present at high
concentrations at sites of allergic inflammation.39 To inves-
tigate dynamic alterations of Mcl-1 as a potential therapeutic
strategy for enhancing resolution of established inflammation
in vivo, we utilized three separate models of neutrophil-
dominant inflammation and two separate pharmacological
agents. Mcl-1 downregulation, by either the CDK inhibitor
AT7519 or the flavone wogonin, led to enhanced resolution of
inflammation with induction of neutrophil apoptosis and
subsequent efferocytosis in vivo. Conversely, the prevention of
AT7519-induced downregulation of Mcl-1 by proteasomal
inhibition attenuated both AT7519-induced neutrophil apop-
tosis in vitro and AT7519-induced resolution of inflammation
in vivo. Although proteasomal inhibition did not itself promote
inflammation and accumulation of neutrophils, this is likely to
represent the early time point studied (24–32 h), as increased
numbers of apoptotic neutrophils were not observed in control
animals until 48 h. Importantly, the strategy of dynamically
reducing Mcl-1 did not rely on either pretreatment or
administration close to the onset of injury as we demonstrated
proresolution effects even at the peak of inflammation, a
clinically relevant time point. Although absolute changes in
rates of apoptosis were low relative to changes in total
neutrophil numbers, it is documented in a number of diverse
experimental and clinical settings that small changes in rates of
apoptosis can have dramatic changes in cellular populations
over time,14,38 most likely because of rapid recognition and
phagocytosis of apoptotic cells. In addition to changes in
inflammatory cell numbers, improvements were also seen in
tissue injury andmarkers of alveolar–capillary barrier integrity.
Although improvements in BAL protein lagged behind
reductions in the neutrophilic infiltrate, this is consistent with
current understanding whereby successful resolution of
inflammatory cell infiltrate accelerates recovery of the alveolar
epitheliumwhose function is essential for successful removal of
proteinaceous alveolar edema.21 Furthermore, we observed
reduced bacterial lung content in our E. coli model despite a
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reduction in inflammatory cell infiltrate and no direct effect of
AT7519 on bacterial growth in vitro. Whether Mcl-1-driven
neutrophil apoptosis and efferocytosis stimulate enhanced
production of endogenous specialized proresolving mediators
with antimicrobial effect19 or whether loss of Mcl-1 may
enhance phagocytosis induced cell death with consequent
enhanced bacterial clearance37 requires further investigation.
Certainly, enhanced neutrophil apoptosis was observed before
changes in lung bacterial titers. Corroboration of the role of
Mcl-1 in controlling resolution of inflammation by use of
knockout or transgenic animals is highly desirable; although a
myeloid-specific Mcl-1 knockout mouse exists,35 this is
essentially a neutropenic mouse and as such is not a good
model system for studying neutrophilic inflammation. To
the authors’ knowledge, a myeloid-specific Mcl-1 transgenic
mouse does not yet exist but would be ideal for future
experiments.
Analysis of cytokines revealed higher IL-6 levels in the LPS
model with AT7519 treatment, whereas IL-6 was unchanged in
the LTA/PepG model. Although IL-6 is considered necessary
for initiation of the acute-phase response, IL-6 and its receptor
have pleiotropic effects with both proinflammatory and anti-
inflammatory activity, with IL-6 having been shown to act in an
anti-inflammatory manner in previous models of LPS-induced
lung inflammation.40,41 Highermonocyte chemotactic protein-
1 levels were also observed at later time points with AT7519
treatment, a cytokine that enhances the recruitment of
monocyte/macrophage cells with an enhanced phagocytic
capacity for apoptotic cells.42,43 In addition, IL-10 was elevated
in the LTA/PepG model at 48 h, a cytokine essential for
resolution of lung inflammation.44 Whether macrophage
cellular phenotype is altered in vivo following Mcl-1 down-
regulation, with effects on subsequent tissue repair and fibrosis,
requires further investigation.
In conclusion, we have demonstrated that dynamic down-
regulation of the prosurvival protein Mcl-1 drives neutrophil
apoptosis and subsequent macrophage clearance, and in doing
so enhances the resolution of both sterile and infection-
mediated established lung inflammation. As such, pharma-
cological agents that target reductions in inflammatory cell
Mcl-1 may offer new therapeutic approaches for the treatment
of infection-associated lung inflammation and other neutro-
phil-dominant human inflammatory diseases.
METHODS
Human neutrophil isolation. Neutrophils were isolated from the
blood of healthy donors (Lothian Research Ethics Committee,
08/S1103/38) and resuspended in Iscove’s modified Dulbecco’s
medium (PAA, Pasching, Austria) with 5% autologous serum at
5 106 per ml (37 1C, 5% CO2) as previously described.11 Neutrophil
purity was routinely 496% with 1–3% contaminating eosinophils.
Neutrophils were incubated with AT7519 (Astex Therapeutics, Astex,
Cambridge, England, UK), E. coli-derived LPS (O127:B8, Sigma,
Dorset, UK), Staphylococcus aureus-derived LTA (Sigma),
S. aureus-derived PepG (Sigma), z-VAD-fmk (v-VAD; Bachem,
Bubendorf, Switzerland), Q-VD-OPh (Q-VD; R&D Systems,
Abingdon, UK), and bortezomib (Selleckchem, Munich, Germany) as
per the figure legends.
Mouse bone marrow-derived neutrophil isolation. Bone marrow,
which contains large numbers of functionally active neutrophils,45 was
removed from femurs and tibias collected fromC57Bl6mice aged 8–12
weeks. Bone marrow was disaggregated and erythrocytes lysed by
hypotonic saline before granulocyte isolation via a discontinuous
Percoll (GE Healthcare, Little Chalfont, UK) gradient as previously
described.46 Following isolation, neutrophils accounted for
77.7±2.1% of the cellular population (determined by morphology).
Assessment of cell viability and apoptosis
Lightmicroscopy. Cytocentrifuge preparations stainedwithDiff-Quick
(Gamidor, Didcot, UK) were assessed for morphological changes
consistent with apoptosis.
Annexin-V/propidium iodide. Viability, apoptosis, and necrosis were
assessed using fluorescein isothiocynate-labeled Annexin-V (Roche,
Welwyn Garden City, UK) and propidium iodide (PI, Sigma) with
samples run on a BD (Oxford, UK) FACScan or LSR Fortessa as
described previously.11 AnnVþ ve/PI ve cells are considered apoptotic,
PIþ ve cells necrotic, and AnnV ve/PI ve cells viable. For mouse BAL
flow cytometry analysis of apoptosis, BAL cells were stainedwith Ly6G
(Biolegend, Cambridge, UK) and F4/80 (AbD Serotec, Oxford, UK)
with AnnV binding of Ly6Gþ ve/F4/80 ve cells analyzed. For MDM
apoptosis, the fungal metabolite gliotoxin (Sigma) was used as a
positive control.
Hypodiploid peak. Cells (50 ml of 5 106) were incubated for 20min
with 250 ml of a solution containing 25 mg PI, 4.84mg sodium citrate
(Sigma), and 0.5 ml Triton X-100 (Sigma) diluted with water. Samples
were run on a BD FACScan flow cytometer with apoptotic nuclei
appearing as a broad hypodiploid DNA peak below the narrow peak of
nuclei with normal DNA content.47
DNA fragmentation assay. Isolated DNA from 2.5 106 neutrophils
(Promega, Southampton, UK; genomic DNA isolation system) was
run on a 1.5% agarose gel precast with 5 ml GelRed (Biotium, Hayward,
CA) and visualized by UV lamp.
HL-60 cell culture and siRNA transfection. HL-60 cells (ATCC,
Middlesex, UK) were cultured in RMPI-1640 (PAA) containing 10%
heat-inactivated fetal calf serum, 2mM L-glutamate, penicillin
(100Uml 1), and streptomycin (100Uml 1). Cells were transfected
with 200 nMMcl-1 siRNAor scrambled sequence siRNA (Dharmacon,
Rockford, IL) using an Amaxa (Cambridge, UK) Nucleofector using
Nucleofector Kit V and setting T-019. HL-60 cell survival and
apoptosis was assessed by changes in forward and side scatter profiles
as well as assessment of hypodiploid peak.47
Westernblotting. Following incubation with compounds as described
in the figure legends, cells were lysed by 0.1% Nonidet P40 in the
presence of protease inhibitors as previously described.11 Following
BCA protein assay (Thermo Scientific, Loughborough, UK), lysates
were run on a 12% sodium dodecyl sulfate gel and transferred onto
polyvinylidene difluoride (Immobilon-P, Millipore, Bedford, MA),
blocked with 5% wt/vol dried milk/Tris-buffered saline/0.1% Tween-
20 before overnight incubation at 4 1C (or 1 h at room temperature for
b-actin) with primary antibodies for Mcl-1 (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA), cleaved caspase-3 (1:1000, Cell
Signalling, Danvers, MA), glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH; 1:10,000, Sigma), or b-actin (1:20,000, Sigma).
Blots were then incubated with the appropriate horseradish perox-
idase-conjugated secondary antibody (Dako, Cambridgeshire, UK)
before incubation with ECL-prime (GE Healthcare), and exposed to
BioMax light-sensitive film (Kodak, Rochester, NY) and processed
through anX-ray developer (Xograph Imaging Systems, Tetbury, UK).
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Assessment of MDM phagocytosis of apoptotic neutrophils. The
7-day-old MDMs (differentiated in the presence of 100 nM
dexamethasone48) were used to assess phagocytosis of cell tracker
green-labeled (1mg per 106 neutrophils, Invitrogen, Carlsbad, CA)
apoptotic neutrophils as previously described.6 Neutrophils treated
with 1 mMAT7519, 10 mMQ-VD, or combinations as per figure legends
for 4.5 h were washed and then 7.5 105 co-incubated withMDMs for
1 h. After 10min of incubation with trypsin-EDTA, resuspended cells
were analyzed by flow cytometry. Cytochalasin D (Calibochem, San
Diego, CA) was used to inhibit MDM phagocytosis. In separate
experiments, MDMs were incubated with AT7519 for 6–8 h before
assessment of phagocytic capacity.
In vivo acute lung inflammation. Female mice (8–12-week-old
C57Bl6) were injected i.t. with 1 mg E. coli-derived (O127:B8) LPS in
50 ml sterile saline, combined S. aureus-derived LTA (150 mg) and
PepG (50 mg), or 1 106 CFUs of E. coli (serotype ATCC25922) grown
to log phase. At 24 h after i.t. challenge, animals received either
30mg kg 1 AT7519 intraperitoneally (10mg kg 1 for E. coli
experiments) in 200 ml sterile saline or vehicle control. For wogonin
experiments animals received 10mg kg 1 wogonin intraperitoneally
in dimethyl sulfoxide or vehicle control. For experiments with
bortezomib, animals were pretreated for 30min at 23.5 h with
0.4mg kg 1 intraperitoneal bortezomib in dimethyl sulfoxide or
vehicle control before administration of AT7519. At indicated time
points, lungs were lavaged with three aliquots of 800 ml sterile ice-cold
saline. BAL fluid was centrifuged at 300 g for 5min with supernatant
from the first lavage stored for biochemical analysis. BAL total protein
was measured by bicinchoninic acid assay (Pierce, Northumberland,
UK), BAL IgM by enzyme-linked immunosorbent assay (ELISA;
eBioscience, Hatfield, UK), and cytokines (TNF-a, IL-6, CCL-2, and
IL-10) were measured by ELISA (R&D Systems). BAL fluid cells were
cytocentrifuged and stained using Diff-Quick and differential counts
performed (Z450 cells counted per slide). Separate lungs for histology
were fixed with 10% formalin (Sigma) before hematoxylin and eosin
staining. For analysis of interstitial lung neutrophils, mice were
perfused with 20ml phosphate-buffered saline and the right lung
digested in collagenase D (Roche) before incubation with anti-CD45
(Biolegend) and anti-Ly6G (Biolegend), with flow analysis in the
presence of flow-check flurospheres (Beckman Coulter, Brea, CA).
Bacterial counts were determined following overnight incubation on
LB agar plates whereas in vitro E. coli growth in the presence ofAT7519
was determined by absorbance (570 nm) every 30min. Resolution
intervals (Ri) were calculated as previously described.
18,19 Briefly, these
were calculated as T50Tmax, where Tmax is the time where neutrophil
numbers were at their maximal numbers (Cmax) and T50 is the time
after Tmax where neutrophil numbers were half-maximal.
Statistical analysis. Results, expressed as mean±s.e.m., were ana-
lyzed using GraphPad Prism by two-way analysis of variance with a
Bonferroni test, one-way analysis of variance with a Newman–Keuls
multiple comparison test, or an unpaired t-test as appropriate. Sig-
nificance was accepted at Po0.05.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
ACKNOWLEDGMENTS
We thank Fiona Rossi and Shonna Johnston for assistance with flow
cytometry; Dr J. Lyons and Astex therapeutics who provided AT7519 as a
kind gift; Drs R.Gray and L. Alessandri for useful discussions. Thisworkwas
funded by the Wellcome Trust (WT094415 to C.D.L.) and the UK Medical
Research Council (G0601481 and MR/K013386/1 to A.G.R. and C.H.).
AUTHOR CONTRIBUTIONS
C.D.L., D.A.D., M.A.T., S.F., J.A.M., K.C.A., C.R., R.D., and A.G.R.
performed research; C.D.L., D.A.D., N.H., C.H., R.D., and A.G.R. designed
research; C.D.L., D.A.D., and A.G.R. wrote the manuscript.
DISCLOSURE
The authors declared no conflict of interest.
& 2014 Society for Mucosal Immunology
REFERENCES
1. Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat.
Rev. Immunol. 6, 173–182 (2006).
2. Fox, S., Leitch, A.E., Duffin, R., Haslett, C. & Rossi, A.G. Neutrophil
apoptosis: relevance to the innate immune response and inflammatory
disease. J. Innate Immun. 2, 216–227 (2010).
3. Serhan, C.N. et al. Resolution of inflammation: state of the art, definitions
and terms. FASEB J. 21, 325–332 (2007).
4. Fournier, B.M. & Parkos, C.A. The role of neutrophils during intestinal
inflammation. Mucosal Immunol. 5, 354–366 (2012).
5. Savill, J.S., Wyllie, A.H., Henson, J.E., Walport, M.J., Henson, P.M. &
Haslett, C.Macrophage phagocytosis of aging neutrophils in inflammation.
Programmed cell death in the neutrophil leads to its recognition by
macrophages. J. Clin. Invest. 83, 865–875 (1989).
6. Michlewska, S., Dransfield, I., Megson, I.L. & Rossi, A.G. Macrophage
phagocytosis of apoptotic neutrophils is critically regulated by the opposing
actions of pro-inflammatory and anti-inflammatory agents: key role for
TNF-alpha. FASEB J. 23, 844–854 (2009).
7. Leitch, A.E., Duffin, R., Haslett, C. & Rossi, A.G. Relevance of granulocyte
apoptosis to resolution of inflammation at the respiratorymucosa.Mucosal
Immunol. 1, 350–363 (2008).
8. Fialkow, L. et al.Neutrophil apoptosis: amarker of disease severity in sepsis
and sepsis-induced acute respiratory distress syndrome. Crit. Care 10,
R155 (2006).
9. Cross, A., Moots, R.J. & Edwards, S.W. The dual effects of TNFalpha on
neutrophil apoptosis are mediated via differential effects on expression of
Mcl-1 and Bfl-1. Blood 111, 878–884 (2008).
10. Alessandri, A.L., Sousa, L.P., Lucas, C.D., Rossi, A.G., Pinho, V. & Teixeira,
M.M. Resolution of inflammation: mechanisms and opportunity for drug
development. Pharmacol. Ther. 11, 00085–00085 (2013).
11. Lucas, C.D. et al. Flavones induce neutrophil apoptosis by down-
regulation of Mcl-1 via a proteasomal-dependent pathway. FASEB J.
27, 1084–1094 (2013).
12. Moulding, D.A., Akgul, C., Derouet, M., White, M.R. & Edwards, S.W.
BCL-2 family expression in human neutrophils during delayed and
accelerated apoptosis. J. Leukoc. Biol. 70, 783–792 (2001).
13. Fotouhi-Ardakani, N.et al.Role formyeloid nuclear differentiation antigen in
the regulation of neutrophil apoptosis during sepsis. Am. J. Respir. Crit.
Care Med. 182, 341–350 (2010).
14. Rossi, A.G. et al. Cyclin-dependent kinase inhibitors enhance the
resolution of inflammation by promoting inflammatory cell apoptosis.
Nat. Med. 12, 1056–1064 (2006).
15. Santo, L. et al. AT7519, a novel small molecule multi-cyclin-dependent
kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta
activation and RNA polymerase II inhibition. Oncogene 29, 2325–2336
(2010).
16. Leitch, A.E., Lucas, C.D., Marwick, J.A., Duffin, R., Haslett, C. &
Rossi, A.G. Cyclin-dependent kinases 7 and 9 specifically regulate
neutrophil transcription and their inhibition drives apoptosis to promote
resolution of inflammation. Cell Death Differ. 29, 80 (2012).
17. Wardle, D.J., Burgon, J., Sabroe, I., Bingle, C.D., Whyte, M.K. &
Renshaw, S.A. Effective caspase inhibition blocks neutrophil apoptosis
and reveals Mcl-1 as both a regulator and a target of neutrophil caspase
activation. PLoS One 6, e15768 (2011).
18. Bannenberg, G.L. et al. Molecular circuits of resolution: formation
and actions of resolvins and protectins. J. Immunol. 174, 4345–4355
(2005).
19. Chiang, N. et al. Infection regulates pro-resolving mediators that lower
antibiotic requirements. Nature 484, 524–528 (2012).
20. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth,
induces apoptosis, and overcomes drug resistance in human multiple
myeloma cells. Cancer Res. 61, 3071–3076 (2001).
21. Matthay, M.A., Ware, L.B. & Zimmerman, G.A. The acute respiratory
distress syndrome. J. Clin. Invest. 122, 2731–2740 (2012).
ARTICLES
MucosalImmunology | VOLUME 7 NUMBER 4 | JULY 2014 867
22. Steinberg, K.P., Milberg, J.A., Martin, T.R., Maunder, R.J., Cockrill, B.A. &
Hudson, L.D. Evolution of bronchoalveolar cell populations in the
adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med.
150, 113–122 (1994).
23. Worthen, G.S., Haslett, C., Rees, A.J., Gumbay, R.S., Henson, J.E. &
Henson, P.M. Neutrophil-mediated pulmonary vascular injury. Synergistic
effect of trace amounts of lipopolysaccharide and neutrophil stimuli on
vascular permeability and neutrophil sequestration in the lung. Am. Rev.
Respir. Dis. 136, 19–28 (1987).
24. Abraham, E., Carmody, A., Shenkar, R. & Arcaroli, J. Neutrophils as early
immunologic effectors in hemorrhage- or endotoxemia-inducedacute lung
injury. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L1137–L1145 (2000).
25. Folkesson, H.G., Matthay, M.A., Hebert, C.A. & Broaddus, V.C. Acid
aspiration-induced lung injury in rabbits is mediated by interleukin-
8-dependent mechanisms. J. Clin. Invest. 96, 107–116 (1995).
26. Koedel, U. et al. Apoptosis is essential for neutrophil functional shutdown
and determines tissue damage in experimental pneumococcal meningitis.
PLoS Pathog. 5, e1000461 (2009).
27. Garrison, S.P. et al. The p53-target gene puma drives neutrophil-mediated
protection against lethal bacterial sepsis.PLoSPathog.6, e1001240 (2010).
28. Dibbert, B. et al. Cytokine-mediated Bax deficiency and consequent
delayed neutrophil apoptosis: a generalmechanism to accumulate effector
cells in inflammation. Proc. Natl. Acad. Sci. USA 96, 13330–13335 (1999).
29. Moulding, D.A., Quayle, J.A., Hart, C.A. & Edwards, S.W.Mcl-1 expression
in human neutrophils: regulation by cytokines and correlation with cell
survival. Blood 92, 2495–2502 (1998).
30. Leuenroth, S.J., Grutkoski, P.S., Ayala, A. & Simms, H.H. Suppression of
PMN apoptosis by hypoxia is dependent on Mcl-1 and MAPK activity.
Surgery 128, 171–177 (2000).
31. Akgul, C., Moulding, D.A., White, M.R. & Edwards, S.W. In vivo localisation
and stability of human Mcl-1 using green fluorescent protein (GFP) fusion
proteins. FEBS Lett. 478, 72–76 (2000).
32. Eickmeier, O. et al. Aspirin-triggered resolvin D1 reduces mucosal
inflammation and promotes resolution in a murine model of acute lung
injury. Mucosal Immunol. 6, 256–266 (2013).
33. Planaguma, A. et al. Lovastatin decreases acute mucosal inflammation via
15-epi-lipoxin A4. Mucosal Immunol. 3, 270–279 (2010).
34. Steimer, D.A., Boyd, K., Takeuchi, O., Fisher, J.K., Zambetti, G.P. &
Opferman, J.T. Selective roles for antiapoptotic MCL-1 during granulocyte
development and macrophage effector function. Blood 113, 2805–2815
(2009).
35. Dzhagalov, I. St, John, A. & He, Y.W. The antiapoptotic protein Mcl-1 is
essential for the survival of neutrophils but not macrophages. Blood 109,
1620–1626 (2007).
36. Liu, H., Perlman, H., Pagliari, L.J. & Pope, R.M. Constitutively
activated Akt-1 is vital for the survival of human monocyte-differentiated
macrophages. Role of Mcl-1, independent of nuclear factor
(NF)-kappaB, Bad, or caspase activation. J. Exp. Med. 194, 113–126
(2001).
37. Marriott, H.M. et al. Dynamic changes in Mcl-1 expression regulate
macrophage viability or commitment to apoptosis during bacterial
clearance. J. Clin. Invest. 115, 359–368 (2005).
38. McGrath, E.E. et al. TNF-related apoptosis-inducing ligand (TRAIL)
regulates inflammatory neutrophil apoptosis and enhances resolution
of inflammation. J. Leukoc. Biol. 90, 855–865 (2011).
39. Brode, S., Farahi, N., Cowburn, A.S., Juss, J.K., Condliffe, A.M. &
Chilvers, E.R. Interleukin-5 inhibits glucocorticoid-mediated apoptosis in
human eosinophils. Thorax 65, 1116–1117 (2010).
40. Ulich, T.R., Yin, S., Guo, K., Yi, E.S., Remick, D. & del Castillo, J.
Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and
transforming growth factor beta inhibit acute inflammation. Am. J. Pathol.
138, 1097–1101 (1991).
41. Ganeshan, K., Johnston, L.K. & Bryce, P.J. TGF-beta1 limits the onset of
innate lung inflammation by promoting mast cell-derived IL-6. J. Immunol.
29, 29 (2013).
42. Liang, J. et al. A macrophage subpopulation recruited by CC chemokine
ligand-2 clears apoptotic cells in noninfectious lung injury. Am. J. Physiol.
Lung Cell Mol. Physiol. 302, L933–L940 (2012).
43. Tanaka, T., Terada, M., Ariyoshi, K. & Morimoto, K. Monocyte chemoat-
tractant protein-1/CCchemokine ligand 2enhances apoptotic cell removal
by macrophages through Rac1 activation. Biochem. Biophys. Res.
Commun. 399, 677–682 (2010).
44. Poe, S.L. et al. STAT1-regulated lung MDSC-like cells produce IL-10 and
efferocytose apoptotic neutrophils with relevance in resolution of bacterial
pneumonia. Mucosal Immunol. 6, 189–199 (2013).
45. Boxio, R., Bossenmeyer-Pourie, C., Steinckwich, N., Dournon, C. &
Nusse, O. Mouse bone marrow contains large numbers of functionally
competent neutrophils. J. Leukoc. Biol. 75, 604–611 (2004).
46. Dorward, D.A. et al. Technical advance: autofluorescence-based sorting:
rapid and nonperturbing isolation of ultrapure neutrophils to determine
cytokine production. J. Leukoc. Biol. 10, 10 (2013).
47. Nicoletti, I.,Migliorati, G., Pagliacci, M.C., Grignani, F. &Riccardi, C. A rapid
and simple method for measuring thymocyte apoptosis by propidium
iodide staining and flow cytometry. J. Immunol. Methods 139, 271–279
(1991).
48. Liu, Y. et al. Glucocorticoids promote nonphlogistic phagocytosis of
apoptotic leukocytes. J. Immunol. 162, 3639–3646 (1999).
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative
Works 3.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
ARTICLES
868 VOLUME 7 NUMBER 4 | JULY 2014 |www.nature.com/mi
